Replimune aims for accelerated approval of melanoma therapy: The company announced Thursday that one-third of melanoma patients who received its genetically engineered herpes virus therapy plus Bristol Myers Squibb’s Opdivo responded to treatment in a Phase 2 trial. These patients had failed previous immunotherapy. Replimune now plans to file for accelerated approval in the second half of the year, and it expects the first patient to be enrolled in its confirmatory study in the third quarter of the year. Replimune’s shares $REPL rose about 25% on Thursday morning.
Structure Therapeutics raises $476M via upsized stock sale: On Monday, the company announced that its oral obesity drug candidate led to significant weight loss in a pair of mid-stage clinical studies. Its share value skyrocketed on the data. On Thursday, Structure said it was selling over 9 million shares at $52.50 apiece in an upsized public offering.